Interim analysis of phase-3 trials of COVAXIN shows 78 percent clinical efficacy - Bharat Biotech - Android

Hyderabad, April 21: Covaxin, a vaccine developed by Bharat Biotech, has demonstrated overall interim clinical efficacy of 78 per cent and 100 per cent efficacy against severe COVID-19, the city-based company said on Wednesday announcing phase 3 interim analysis results ofthe vaccine.